AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio ... Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys.

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its covid antibody cocktail as ...

SHANGHAI, Nov. 7 (Xinhua) -- In the vast and intricately designed National Exhibition and Convention Center (Shanghai), where ...

SHANGHAI, Nov. 7 (Xinhua) -- In the vast and intricately designed National Exhibition and Convention Center (Shanghai), where ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...

Chicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the ... AbbVie ABBV and Sanofi SNY. Johnson & Johnson’s third-quarter results were strong as it beat ...

For Sanofi, notable drugs like the multiple sclerosis treatment Aubagio have ... It wouldn’t be surprising to see Sanofi on ...

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could ...